ABSTRACT

Angiotensin II is an octapeptide with potent vasoconstrictor activities. The recent publication of favorable data from ATHOS-3 trial in 2017 was followed by FDA priority review approval of GIAPREZA (LJPC-501) for management of hypotension in states of vasodilatory shock. Aiming to summarize the current status of clinical research on the therapeutic use of Angiotensin II in patients with shock, we searched for published and ongoing clinical trials, and reviewed the cornerstone research articles on the topic. It appears that the existing research on clinical use of Angiotensin II is rather scarce, however, with the recent approval under priority review, a boost in clinical research is highly anticipated, in order to provide further insight into the potential implications of the synthetic octapeptide in various refractory hypotensive states. Keywords: Refractory circulatory failure, sepsis, vasopressors, peptide hormone, FDA, novel therapeutics
Publication date: 01/03/2022

https://ijbpas.com/pdf/2022/March/MS_IJBPAS_2022_5941.pdf

Download PDF
https://doi.org/10.31032/IJBPAS/2022/11.3.5941